PCM
TCRT icon

Piermont Capital Management’s Alaunos Therapeutics TCRT Stock Holding History

Piermont Capital Management’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-570
Closed -$532K – 272
2017
Q2 		$532K Sell
570
-102
-15% -$100K 0.15% 223
2017
Q1 		$639K Buy
+672
New +$626K 0.15% 211
2015
Q3 		– Sell
-320
Closed -$576K – 251
2015
Q2 		$576K Buy
+320
New +$497K 0.17% 139

Other funds holding TCRT

TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
MVP
Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Piermont Capital Management's TCRT Position: Q3 2017 in Review

Piermont Capital Management sold out of Alaunos Therapeutics (TCRT) in Q3 2017, closing a stake of 570 shares — an estimated $532K sold.

Piermont Capital Management first reported a position in TCRT in Q2 2015 and held it in 3 quarters. The position peaked at $639K in Q1 2017. 122 funds tracked by Wall St. Rank hold TCRT as of Q3 2017.

  • Piermont Capital Management reported no remaining Alaunos Therapeutics position as of Q3 2017 after selling out during the quarter.
  • Piermont Capital Management sold 570 Alaunos Therapeutics shares in Q3 2017, an estimated $532K.
  • Piermont Capital Management first reported a position in Alaunos Therapeutics in Q2 2015 and held it in 3 quarters.
  • Piermont Capital Management's Alaunos Therapeutics position peaked at $639K in Q1 2017.
  • 122 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q3 2017.

Based on Piermont Capital Management's 13F filing for Q3 2017, filed 14 Nov 2017.